THE following companies saw new developments that may affect trading of their securities on Wednesday (Aug 3):

HEALTHCARE services provider TalkMed Group reported a 12.2 per cent increase in net profit for its first half ended Jun 30, 2022 on the back of higher revenue.

TECHNOLOGY specialist TalkMed Group on Monday (Mar 28) said it received in-principle approval from the Singapore Exchange (SGX) on Mar 25 for its transfer to the bourse's mainboard.

Lee has also been keeping an eye out for suitable growth opportunities. As of Dec 31 2021, SPCH has spent $2.4 million, or 67.8% of the $3.54 million raised during its IPO, to expand its business operations locally and regionally.Aside from the balance of $1.14 million in IPO funds, SPCH has amassed...

TECHNOLOGY specialist TalkMed Group 5G3 's board of directors said it intends to transfer the listing of the company from the Catalist board of the Singapore Exchange (SGX) to the mainboard.

Medical oncology and stem cell services provider TalkMed Group saw its earnings jump 18.5% to $14.3 million for the 2HFY2021 ended December, from $12.1 million a year ago. This brings earnings for the FY2021 to $25.1 million, 10.3% higher y-o-y. Earnings per share (EPS) climbed to 1.08 cents in th...

TalkMed Chongqing – the wholly-owned subsidiary of SGX-listed TalkMed Group has established Chongqing Medtech Health Management (CMHM). This is a joint venture company set up with Chongqing Yijiasheng Pharma Technology (CYPT) and Chongqing Tuozhen Information Technology (CTIT). CMHM will assist pa...

ONCOLOGY specialist TalkMed Group posted a 1.1 per cent rise in net profit to S$10.8 million for the six months ended June, even as its patient numbers were hit by travel restrictions, the Catalist-listed company announced on Tuesday evening.